‘Pharma Bro’ Shkreli Loses Bid to Ax Proof of Prior Drug Markup

Former pharma executive Martin Shkreli lost a bid to exclude pricing tactics at his early startup Retrophin Inc. as evidence in the FTC’s antitrust lawsuit over his role in Vyera Pharmaceuticals’ 4,000% markup of an anti-parasitic drug.

The ruling allows the Federal Trade Commission and the states joining its suit to introduce the conduct as evidence to show that Shkreli’s intent on raising Daraprim’s prices at Vyera was a deliberate strategy to block generic competitors and that it wasn’t a one-time aberration.

Shkreli, who’s now in jail, allegedly obtained control of two drugs, Chenodal and Thiola, at Retrophin and raised ...